These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 25104581)
1. Health-related quality of life as a prognostic factor in patients with advanced cancer. Steel JL; Geller DA; Robinson TL; Savkova AY; Brower DS; Marsh JW; Tsung A Cancer; 2014 Dec; 120(23):3717-21. PubMed ID: 25104581 [TBL] [Abstract][Full Text] [Related]
2. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis. Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787 [No Abstract] [Full Text] [Related]
3. Quality of life and survival analysis of patients undergoing transarterial chemoembolization for primary hepatic malignancies: a prospective cohort study. Eltawil KM; Berry R; Abdolell M; Molinari M HPB (Oxford); 2012 May; 14(5):341-50. PubMed ID: 22487072 [TBL] [Abstract][Full Text] [Related]
4. The Prognostic Value of Cytokeratin and Sal-Like Protein 4 Expression in Hepatocellular Carcinoma and Intra-Hepatic Cholangiocarcinoma in Taiwan. Lai YS; Cheng CC; Lee MT; Chao WT; Lai YC; Hsu YH; Liu YH Int J Med Sci; 2018; 15(14):1746-1756. PubMed ID: 30588199 [No Abstract] [Full Text] [Related]
5. Hepatitis B virus-related combined hepatocellular-cholangiocarcinoma: clinicopathological and prognostic analysis of 390 cases. Chu KJ; Lu CD; Dong H; Fu XH; Zhang HW; Yao XP Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):192-9. PubMed ID: 24370644 [TBL] [Abstract][Full Text] [Related]
6. Combined hepatocellular cholangiocarcinoma: prognostic factors investigated by computed tomography/magnetic resonance imaging. Lin G; Toh CH; Wu RC; Ko SF; Ng SH; Chou WC; Tseng JH Int J Clin Pract; 2008 Aug; 62(8):1199-205. PubMed ID: 17537192 [TBL] [Abstract][Full Text] [Related]
7. [Analysis of prognostic factors after curative resection for combined hepatocellular and cholangiocarcinoma]. Kim W; Lee JH; Kim YJ; Yoon JH; Suh KS; Lee KU; Jang JJ; Lee HS Korean J Gastroenterol; 2007 Mar; 49(3):158-65. PubMed ID: 18172344 [TBL] [Abstract][Full Text] [Related]
8. Progenitor gene DLK1 might be an independent prognostic factor of liver cancer. Jin ZH; Yang RJ; Dong B; Xing BC Expert Opin Biol Ther; 2008 Apr; 8(4):371-7. PubMed ID: 18352842 [TBL] [Abstract][Full Text] [Related]
9. Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Kim KH; Lee SG; Park EH; Hwang S; Ahn CS; Moon DB; Ha TY; Song GW; Jung DH; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ Ann Surg Oncol; 2009 Mar; 16(3):623-9. PubMed ID: 19130133 [TBL] [Abstract][Full Text] [Related]
10. Elevated neutrophil-to-lymphocyte ratio and predominance of intrahepatic cholangiocarcinoma prediction of poor hepatectomy outcomes in patients with combined hepatocellular-cholangiocarcinoma. Chiu TJ; Chen YJ; Kuo FY; Chen YY PLoS One; 2020; 15(12):e0240791. PubMed ID: 33306714 [TBL] [Abstract][Full Text] [Related]
11. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Lee WS; Lee KW; Heo JS; Kim SJ; Choi SH; Kim YI; Joh JW Surg Today; 2006; 36(10):892-7. PubMed ID: 16998683 [TBL] [Abstract][Full Text] [Related]
13. Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis. Liu WR; Tian MX; Tao CY; Tang Z; Zhou YF; Song SS; Jiang XF; Wang H; Zhou PY; Qu WF; Fang Y; Ding ZB; Zhou J; Fan J; Shi YH BMC Cancer; 2020 Jul; 20(1):642. PubMed ID: 32650743 [TBL] [Abstract][Full Text] [Related]
14. Longterm prognosis of combined hepatocellular carcinoma-cholangiocarcinoma following liver transplantation and resection. Jung DH; Hwang S; Song GW; Ahn CS; Moon DB; Kim KH; Ha TY; Park GC; Hong SM; Kim WJ; Kang WH; Kim SH; Yu ES; Lee SG Liver Transpl; 2017 Mar; 23(3):330-341. PubMed ID: 28027599 [TBL] [Abstract][Full Text] [Related]
15. Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers. Wakizaka K; Yokoo H; Kamiyama T; Ohira M; Kato K; Fujii Y; Sugiyama K; Okada N; Ohata T; Nagatsu A; Shimada S; Orimo T; Kamachi H; Taketomi A J Gastroenterol Hepatol; 2019 Jun; 34(6):1074-1080. PubMed ID: 30462849 [TBL] [Abstract][Full Text] [Related]
17. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Patt YZ; Hassan MM; Aguayo A; Nooka AK; Lozano RD; Curley SA; Vauthey JN; Ellis LM; Schnirer II; Wolff RA; Charnsangavej C; Brown TD Cancer; 2004 Aug; 101(3):578-86. PubMed ID: 15274071 [TBL] [Abstract][Full Text] [Related]
18. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Yano Y; Yamamoto J; Kosuge T; Sakamoto Y; Yamasaki S; Shimada K; Ojima H; Sakamoto M; Takayama T; Makuuchi M Jpn J Clin Oncol; 2003 Jun; 33(6):283-7. PubMed ID: 12913082 [TBL] [Abstract][Full Text] [Related]
19. Clinicopathological factors impact the survival outcome following the resection of combined hepatocellular carcinoma and cholangiocarcinoma. Yap AQ; Chen CL; Yong CC; Kuo FY; Wang SH; Lin CC; Liu YW; Lin TL; Li WF; Millan CA; Wang CC Surg Oncol; 2013 Mar; 22(1):55-60. PubMed ID: 23102615 [TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Akiba J; Nakashima O; Hattori S; Tanikawa K; Takenaka M; Nakayama M; Kondo R; Nomura Y; Koura K; Ueda K; Sanada S; Naito Y; Yamaguchi R; Yano H Am J Surg Pathol; 2013 Apr; 37(4):496-505. PubMed ID: 23388123 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]